Lipocine Announces LPCN 1144 Clinical Trial Results Selected for Presentation at 2019 NASH-TAG Conference

Lipocine Announces LPCN 1144 Clinical

Trial Results Selected for Presentation at 2019 NASH-TAG Conference

SALT LAKE CITY, UT, December 21, 2018 -

Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144

results as part of the 2019 NASH-TAG Conference. The presentation will highlight data from multiple clinical trials of LPCN 1144

in potential non-alcoholic fatty liver disease ("NAFLD") / non-alcoholic steatohepatitis ("NASH") patients.

The NASH-TAG Conference 2019 is being held January 3rd - 5th in Park City, UT.

Presentation Details

"The observed reduction in serum liver enzymes and lipids

highlight the promise of LPCN 1144 as a potential therapy for NASH," stated Mahesh Patel, Ph.D., Lipocine's Chairman, President

and Chief Executive Officer. "We look forward to sharing the results from our clinical trials with LPCN 1144 as part of the

2019 NASH-TAG Conference," Dr. Patel further stated.

Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using

its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes four development programs TLANDO,

LPCN 1144, LPCN 1111 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed

to help restore normal testosterone levels in hypogonadal men. TLANDO received a Complete Response Letter from the FDA on May 8,

2018. LPCN 1144, an oral prodrug of bioidentical testosterone, is being developed as a treatment of non-alcoholic steatohepatitis

("NASH") and is currently being studied in two proof-of-concept clinical studies. LPCN 1111, a novel oral prodrug of

testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily

dosing and is currently in Phase 2 testing. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate

indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. An End of Phase

2 meeting with the FDA has been completed. For more information, please visit www.lipocine.com

Forward-Looking Statements

This release contains

"forward looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation

Reform Act of 1995 and include statements that are not historical facts regarding Lipocine's product candidates and related

clinical trials and the FDA review process relating to its product candidates, the path to approvability by the FDA of Lipocine's

development programs, the potential uses and benefits of our product candidates, including LPCN 1144, and our product development

efforts. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation,

the risks that the FDA will not approve any of our products, risks related to our products, expected product benefits not being

realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks

related to the FDA approval process including the receipt of regulatory approvals, the results and timing of clinical trials, patient

acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks

detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K

and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly

any forward-looking statements contained in this release, except as required by law.

Executive Vice President & Chief

Phone: (801) 994-7383

Phone: (646) 597-6979